Research Article

Prevalence of Sleep-Disordered Breathing in Prader–Willi Syndrome

Table 3

Regression analysis for AHI and REM-AHI (univariate analysis) with age, BMI, symptoms, GH therapy and AHI, REM-AHI in patients with PWS.

VariablesLogged AHILogged REM-AHI
eβ (95% CI) valueeβ (95% CI) value

Age, years1.01 (0.9, 1.1)0.6801.05 (0.9, 1.1)0.170
Gender (male)1.41 (0.6, 3.3)0.4150.99 (0.4, 2.3)0.999
BMI (kg/m2)1.02 (0.9, 1.0)0.2391.03 (1.1, 1.1)0.031
GH therapy (yes)1.01 (0.4, 2.5)0.9890.98 (0.4, 2.3)0.952
History of snoring (yes)1.70 (0.6, 4.9)0.3021.97 (0.7, 5.3)0.161
History of apnea (yes)1.83 (0.8, 4.2)0.1482.06 (1.0, 4.4)0.063
Reported adenoid/tonsil hypertrophy (yes)0.75 (0.3, 2.2)0.5761.08 (0.4, 3.1)0.872

BMI, body mass index; GH, hormone therapy. Estimates of effect size are presented as odds ratios and 95% confidence intervals as exponentiated β-coefficients (eβ) for the continuous logged variables for AHI and REM-AHI. Exponentiated β-values indicate the percentage change in the outcome per unit change in the predictor variable.